

# Wenâ€™Zhao Zhong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6662866/publications.pdf>

Version: 2024-02-01

43  
papers

1,666  
citations

516215

16  
h-index

329751

37  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1749  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-III A (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 139-148.	5.1	436
2	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2235-2245.	0.8	193
3	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-III A (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 713-722.	0.8	159
4	Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1912-1923.	0.5	105
5	Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. <i>EBioMedicine</i> , 2020, 60, 102990.	2.7	95
6	Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. <i>Cancer Communications</i> , 2021, 41, 287-302.	3.7	74
7	Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4929-4937.	3.2	67
8	Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. , 2022, 10, e003534.		56
9	The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 71358-71370.	0.8	51
10	Genomic signatures define three subtypes of EGFR-mutant stage III non-small-cell lung cancer with distinct adjuvant therapy outcomes. <i>Nature Communications</i> , 2021, 12, 6450.	5.8	48
11	Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2279-2290.	0.8	39
12	Timing and Origins of Local and Distant Metastases in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1136-1148.	0.5	39
13	Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. <i>Lung Cancer</i> , 2020, 139, 118-123.	0.9	33
14	MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. <i>Experimental Hematology and Oncology</i> , 2021, 10, 52.	2.0	28
15	Application of indocyanine green fluorescence for precision sublobar resection. <i>Thoracic Cancer</i> , 2019, 10, 624-630.	0.8	21
16	Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. , 2021, 9, e002312.		21
17	Electromagnetic navigation bronchoscopic localization versus percutaneous CT-guided localization for thoracoscopic resection of small pulmonary nodules. <i>Thoracic Cancer</i> , 2021, 12, 468-474.	0.8	20
18	Lung Cancer Treatment Disparities in China: A Question in Need of an Answer. <i>Oncologist</i> , 2014, 19, 1084-1090.	1.9	18

#	ARTICLE	IF	CITATIONS
19	Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. <i>Journal of Thoracic Disease</i> , 2015, 7, 1181-8.	0.6	17
20	Randomized Trial of an Improved Drainage Strategy Versus Routine Chest Tube After Lung Wedge Resection. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1040-1046.	0.7	16
21	Prophylactic air extraction strategy after thoroscopic wedge resection. <i>Thoracic Cancer</i> , 2018, 9, 1406-1412.	0.8	14
22	Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 805-815.e3.	0.4	12
23	Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis. <i>Journal of Thoracic Disease</i> , 2015, 7, 1205-12.	0.6	11
24	Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100257.	0.6	11
25	Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers. <i>Annals of Thoracic Surgery</i> , 2020, 109, 856-863.	0.7	10
26	Wait-and-See Treatment Strategy Could be Considered for Lung Adenocarcinoma with Special Pleural Dissemination Lesions, and Low Genomic Instability Correlates with Better Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 3808-3818.	0.7	10
27	Genomic Evolution of Lung Cancer Metastasis: Current Status and Perspectives. <i>Cancer Communications</i> , 2021, 41, 1252-1256.	3.7	8
28	Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 1051.	1.1	6
29	A three-dimensional printing navigational template combined with mixed reality technique for localizing pulmonary nodules. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 32, 552-559.	0.5	6
30	Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients. <i>Chinese Journal of Cancer</i> , 2017, 36, 53.	4.9	5
31	Drainage tube hole suture improvement: Removal-free stitches. <i>Thoracic Cancer</i> , 2019, 10, 1827-1833.	0.8	5
32	Three-dimensional printed navigational template for localizing small pulmonary nodules: A case-controlled study. <i>Thoracic Cancer</i> , 2020, 11, 2690-2697.	0.8	5
33	Identification of heritable rare variants associated with early-stage lung adenocarcinoma risk. <i>Translational Lung Cancer Research</i> , 2022, 11, 509-522.	1.3	5
34	Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 5822-5832.	0.6	4
35	Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100297.	0.7	4
36	Watershed analysis of the target pulmonary artery for real-time localization of non-palpable pulmonary nodules. <i>Translational Lung Cancer Research</i> , 2021, 10, 1711-1719.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Precise resection of multiple pulmonary nodules using a three-dimensional reconstruction model: A case report. <i>Thoracic Cancer</i> , 2021, 12, 970-973.	0.8	3
38	Minimally invasive, multi-disciplinary approach for surgical management of a mediastinal congenital bronchogenic cyst in a 6-month-old infant. <i>Journal of Thoracic Disease</i> , 2017, 9, E743-E747.	0.6	2
39	Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer – Authors' reply. <i>Lancet Oncology</i> , 2018, 19, e127.	5.1	2
40	Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter $\leq 7$ cm) non-small cell lung cancers. <i>Thoracic Cancer</i> , 2022, , .	0.8	2
41	New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019. <i>Journal of Thoracic Oncology</i> , 2022, 17, 588-591.	0.5	1
42	The superstars of precision medicine – EGFR inhibitors in adjuvant treatment of lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, E11-E13.	0.6	0
43	ASO Author Reflections: Lung Adenocarcinoma with Accidental Invisible Pleural Dissemination Lesions: Wait-and-See Strategy for Tumors with Indolent Biologic Characteristics. <i>Annals of Surgical Oncology</i> , 2020, 27, 3819-3820.	0.7	0